Last updated: June 15, 2026
Malarone Pediatric is a fixed-dose pediatric formulation of atovaquone + proguanil hydrochloride (brand name used for children). The supplier picture is typically segmented into (1) API manufacturers for atovaquone and proguanil HCl, (2) formulation/finished-dose contract manufacturers (CMOs) and packagers, and (3) US market distributors and wholesalers.
Actionable note for sourcing and diligence: Malarone Pediatric is not an API commodity listing. It is a finished branded pediatric drug, so the highest-confidence “supplier” view comes from FDA linkage (Orange Book / labeling) tied to the commercial manufacturer/labeler, then cross-checking CMOs and packaging sites used in that product’s commercial supply chain.
Who supplies Malarone Pediatric in the US market?
Answer: The product is supplied through the branded drug labeler and its supply chain, with finished-dose manufacturing and packaging typically performed under global contracts by one or more GMP facilities.
What to look for in authoritative supplier records
- FDA labeler and manufacturer of record shown on the marketed product labeling (package insert).
- NDC-specific data in FDA systems: labeler, dosage form, and strength.
- Orange Book listings (if applicable for the specific branded presentation) for the drug product’s holder/manufacturer identifiers.
- Wholesaler/distributor coverage for the NDC: chain drug distribution and hospital group purchasing.
Common sourcing channels for a branded pediatric antimalarial
- Large US wholesalers (for routine distribution)
- Specialty pediatric purchasing channels (pediatrics-focused procurement)
- Group purchasing organizations (GPOs) used by hospitals/clinics
- Import channels if the product is allocated or temporarily scarce (often under the same labeler)
Which companies manufacture the atovaquone API used in Malarone Pediatric?
Answer: Atovaquone is a specialized API produced by a limited set of global API suppliers; Malarone Pediatric’s final dose uses atovaquone from the brand’s approved supply chain.
API supplier diligence targets
- DMF holders for atovaquone (for US filings)
- GMP status and site approvals
- Demonstrated supply capacity for pediatric-grade formulations
How atovaquone supplier selection affects pediatric supply
- Particle size control and polymorph issues can affect dissolution behavior
- Stability and moisture sensitivity impact shelf life for pediatric suspensions/tablets depending on the presentation
- Supply interruptions at atovaquone API sites can cascade into pediatric shortages
Which companies manufacture the proguanil hydrochloride (HCl) API used in Malarone Pediatric?
Answer: Proguanil HCl is also supplied by a constrained set of API producers with established regulatory dossiers.
Supplier diligence targets
- DMF coverage for proguanil HCl (US)
- Consistency of impurity profile and salt form control
- Ability to meet pediatric formulation specifications
Downstream effects
- Impurity constraints can drive lot rejections and delay release
- Salt form consistency affects bioavailability and tablet/suspension performance
What is the CMO/contract manufacturing and packaging footprint for Malarone Pediatric?
Answer: The branded pediatric antimalarial is typically produced and packaged through a mix of:
- Finished-dose manufacturing sites (drug product)
- Primary packaging (bottles/blisters depending on presentation)
- Secondary packaging and labeling operations
High-signal documents for identifying CMOs
- FDA labeling and manufacturing section of the package insert
- NDC-level manufacturing/labeling data
- GMP site registrations linked to the drug product
Why packaging is supplier-critical for pediatrics
- Pediatric dosing accuracy drives QA stringency (labeling and concentration)
- Child-resistant packaging and lot traceability requirements increase operational complexity
- Cold-chain is not required, but moisture/light stability still constrains packaging choices
What dosage form strengths exist for Malarone Pediatric, and how does that change suppliers?
Answer: Supplier assignments can differ by presentation (tablet strength, formulation type) and region because manufacturing lines and packaging formats are site-specific.
Typical supplier variability
- Tablet strength variants may be produced on different line equipment
- Packaging formats (bottle vs blister) can require different line clearances
- Pediatric-only SKUs can be manufactured less frequently, which increases lead-time and allocation risk
How can you map Malarone Pediatric suppliers using NDC, labeler, and FDA records?
Answer: Build the supplier chain in three steps:
- Identify the NDC(s) for the exact pediatric presentation and strength used in procurement.
- Extract the FDA labeler/manufacturer of record from the NDC.
- Link that labeler to manufacturing sites using package labeling and FDA listings.
Outputs to produce for sourcing
- One table per NDC: labeler, dosage form, strength, and manufacturer of record
- For each NDC: suspected or confirmed manufacturing/packaging sites
- Compliance flags (GMP warnings, recent site changes) if present in public records
Which distributors supply Malarone Pediatric to US pharmacies and hospitals?
Answer: Distribution is typically via the branded manufacturer’s contracted wholesalers and specialty distributors serving:
- Retail chains
- Mail-order pharmacies
- Hospital formularies and supply departments
Procurement best practice
- Place orders by NDC and lot/batch where feasible
- Use historical fill-rate data by distributor and account for pediatric demand volatility
What happens to supply if atovaquone or proguanil API suppliers change?
Answer: Changes in API manufacturing or DMF reference can trigger:
- Regulatory bridging requirements (to show product equivalence)
- Increased QA release testing and potential lot holds
- Temporary supply constraints, especially for pediatric presentations
Key risk points
- Impurity profile drift
- Polymorph or particle size differences
- Supplier capacity shifts during global demand spikes
How strong is the supplier concentration risk for Malarone Pediatric?
Answer: Concentration risk is usually elevated for fixed-dose pediatric antimalarials because:
- Active ingredients are specialized
- Pediatric SKUs have lower production frequency than adult brands
- API-to-finished-dose conversion depends on a limited set of GMP sites
Commercial risk lens
- Expect higher volatility during malaria season peaks and in markets with procurement surges
- Pediatric formulations can be constrained earlier than adult SKUs when API supply is tight
What supplier options exist outside the brand (authorized generics, imports, or alternates)?
Answer: For a branded pediatric antimalarial, alternatives generally fall into:
- Other pediatric antimalarial formulations (different dosing regimens or combinations)
- Authorized supply channels or imports under the same brand/labeler
- Different manufacturers for the same product in certain markets
Supplier mapping method
- Compare NDC labelers by presentation
- Track whether the same labeler uses multiple manufacturers across time
Key Takeaways
- Malarone Pediatric’s “supplier” chain is best defined by NDC-specific labeler/manufacturer of record, then mapped to API and CMO sites through FDA-linked documentation.
- Atovaquone and proguanil HCl are the upstream critical nodes; disruptions at those APIs can directly constrain pediatric supply.
- Packaging and labeling suppliers can differ by presentation and strength, so NDC-level specificity matters for procurement.
- Supplier concentration risk is typically higher for pediatric fixed-dose antimalarials due to specialized inputs and lower production frequency.
FAQs
- Which NDCs correspond to Malarone Pediatric and who is the FDA labeler for each?
- Are atovaquone and proguanil API suppliers interchangeable for Malarone Pediatric without regulatory changes?
- Do different Malarone Pediatric presentations (strengths/forms) have different manufacturing/packaging sites?
- How do supply-chain constraints on atovaquone affect pediatric antimalarial availability?
- What distributor networks are most reliable for procuring Malarone Pediatric during allocation periods?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. Drug Label Information (Structured Product Labeling / labeling PDFs). FDA.
- U.S. FDA Center for Drug Evaluation and Research. Drug Master Files (DMF) and related guidance documents. FDA.
